Funding for this research was provided by:
Direcció General d’Universitat, Investigació i Ciència, GVA (AICO/2018/090)
Instituto de Salud Carlos III (PI15/00665, PI19-01359)
Spanish Ministerio de Economía y Competitividad, through the “Severo Ochoa” Programme for Centres of Excellence in R&D (SEV-2017-0723)
Received: 6 April 2020
Accepted: 3 August 2020
First Online: 12 August 2020
Ethics approval and consent to participate
: This study was approved by the ethics committee at the Miguel Hernandez University (code number# UMH.iNJS.01.18), and it was carried out in accordance with the Helsinki Declaration regarding research on humans. All human samples were collected from national Brain banks: Banco de Tejidos Neurológicos, Fundación CIEN-Unidad de Investigación Proyecto Alzheimer (UIPA: Madrid, Spain), and the Biobanco en Red de la Región de Murcia (Biobanc-Mur, Murcia, Spain), that obtained informed consent from all patients or their relatives.
: “Not applicable”
: All the authors who contributed to this work agree with the presented findings. The authors are inventors of a patent submitted for the use of sAPP glycoforms as potential AD biomarkers. The authors have no other competing interests to disclose in connection to this article.